Summary
Gilead Sciences, Inc. (GILD) filed an 8-K report on November 17, 2014, to announce the entry into a material definitive agreement related to a significant debt issuance. On November 12, 2014, the company entered into an underwriting agreement for the sale of $500 million in 2.350% Senior Notes due 2020, $1.75 billion in 3.500% Senior Notes due 2025, and $1.75 billion in 4.500% Senior Notes due 2045. This substantial capital raise, totaling $4 billion, was facilitated through a public offering registered under Form S-3. The net proceeds from this issuance are earmarked for general corporate purposes. Gilead indicated these funds may be used for repaying existing indebtedness, working capital needs, and repurchasing its common stock under its authorized share repurchase program. The filing also details supplemental indenture agreements and exhibits related to the terms, conditions, and legal validity of these new senior notes.
Key Highlights
- 1Gilead Sciences issued $4 billion in aggregate principal amount of Senior Notes across three maturities: 2020, 2025, and 2045.
- 2The notes carry coupon rates of 2.350% (2020), 3.500% (2025), and 4.500% (2045).
- 3The debt issuance was conducted through an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC.
- 4Proceeds are designated for general corporate purposes, including debt repayment, working capital, and share repurchases.
- 5The filing includes the Underwriting Agreement and a Fourth Supplemental Indenture with Wells Fargo Bank, National Association as Trustee.
- 6The new notes are governed by indentures that contain restrictions on secured indebtedness, sale and leaseback transactions, and require repurchase upon certain change of control events.